Lutetium-177 dotatate

Approved Use:

• Treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults

Dose: 

• 200 mCi every 8 weeks for a total of 4 doses

​Brand Name: Lutathera®
Manufacturer: Advanced Accelerator Applications USA, Inc. (AAA)
Package Insert  
Product Website
How Supplied: 200 mCi single-dose vial
Volume: 20.5 - 25 mL (adjusted to provide 200 mCi activity)
Calibration:
Expiration: 72 hours
NDC#: 69488-003-01

Clinical Guidelines:

• ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lu-177 DOTATATE Therapy (2020)
• NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE (2019)